MELISSA LAMB: Open Payments
NPI 1013998038 · NEWPORT, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,021 in 59 payments from 19 companies in 2025. Trend: 2023 $1,572 · 2024 $1,766 · 2025 $1,021
Food & beverage: $1,021
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $184 |
| AstraZeneca Pharmaceuticals LP | 9 | $171 |
| Novo Nordisk Inc | 10 | $140 |
| ABBVIE INC. | 5 | $97 |
| PFIZER INC. | 4 | $66 |
| Astellas Pharma US Inc | 2 | $55 |
| E.R. Squibb & Sons, L.L.C. | 3 | $49 |
| Dexcom, Inc. | 2 | $46 |
| Phathom Pharmaceuticals, Inc. | 1 | $30 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
Products named: TRELEGY ELLIPTA, Ozempic, AIRSUPRA, Veozah, ELIQUIS, FARXIGA, Dexcom G6 Transmitter, UBRELVY.
Industry payments across TN — which companies pay providers there.
